These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 19092365

  • 21. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.
    Ghali JK, Zmily HD, Farah JO, Daifallah S.
    IDrugs; 2010 Nov; 13(11):782-92. PubMed ID: 21046526
    [Abstract] [Full Text] [Related]

  • 22. Vasopressin receptor antagonists: pharmacological tools and potential therapeutic agents.
    Streefkerk JO, van Zwieten PA.
    Auton Autacoid Pharmacol; 2006 Apr; 26(2):141-8. PubMed ID: 16553642
    [Abstract] [Full Text] [Related]

  • 23. Vasopressin-receptor antagonists in heart failure.
    Schweiger TA, Zdanowicz MM.
    Am J Health Syst Pharm; 2008 May 01; 65(9):807-17. PubMed ID: 18436727
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Vasopressin antagonists in the management of heart failure.
    Rossi J, Orlandi C, Gheorghiade M.
    Expert Rev Cardiovasc Ther; 2007 Mar 01; 5(2):323-30. PubMed ID: 17338675
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Non-peptide arginine-vasopressin antagonists: the vaptans.
    Decaux G, Soupart A, Vassart G.
    Lancet; 2008 May 10; 371(9624):1624-32. PubMed ID: 18468546
    [Abstract] [Full Text] [Related]

  • 30. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.
    Prog Brain Res; 2008 May 10; 170():473-512. PubMed ID: 18655903
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Treatment options for hyponatremia in heart failure.
    Goldsmith SR.
    Congest Heart Fail; 2010 Jul 10; 16 Suppl 1():S15-8. PubMed ID: 20653706
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure.
    Hori M.
    Future Cardiol; 2013 Mar 10; 9(2):163-76. PubMed ID: 23463968
    [Abstract] [Full Text] [Related]

  • 39. Vasopressin and vasopressin antagonists in heart failure and hyponatremia.
    Farmakis D, Filippatos G, Kremastinos DT, Gheorghiade M.
    Curr Heart Fail Rep; 2008 Jun 10; 5(2):91-6. PubMed ID: 18765079
    [Abstract] [Full Text] [Related]

  • 40. Vasopressin antagonists: Pharmacotherapy for the treatment of heart failure.
    Reilly T, Schork MR.
    Ann Pharmacother; 2010 Apr 10; 44(4):680-7. PubMed ID: 20332337
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.